Table 1 Patient characteristics
Characteristic | Median (range) or number of patients (%) |
|---|---|
Age at diagnosis, years | 58.7 years (45.6–84.1) |
Gender | |
-Male | 16 (69.6%) |
-Female | 7 (30.4%) |
Cancer type | |
-NSCLC | 16 (69.6%) |
-RCC | 4 (17.4%) |
-Melanoma | 3 (13.0%) |
ECOG Performance Status | |
-0 | 5 (21.7%) |
-1 | 12 (52.2%) |
-2 | 6 (26.1%) |
Smoking history | |
-Current | 4 (17.4%) |
-Former | 8 (34.8%) |
-Never | 10 (13.0%) |
-Unknown | 1 (4.4%) |
Immune Checkpoint Inhibitor | |
-Nivolumab | 22 (95.7%) |
-Pembrolizumab | 1 (4.3%) |
Previous lines of therapy | |
-0–1 | 11 (47.8%) |
-2–3 | 7 (30.4%) |
-> 3 | 5 (21.7%) |
Molecular aberrationa | |
-KRAS mutation | 7 (30.4%) |
-BRAF mutation | 2 (8.7%) |
-EGFR mutation | 1 (4.4%) |
-NRAS mutation | 1 (4.4%) |
-TP53 | 1 (4.4%) |
-Wildtype | 6 (26.1%) |
PD-L1 Expression | |
-0% | 1 (4.4%) |
-1–5% | 1 (4.4%) |
-5–10% | 1 (4.4%) |
-10–20% | 1 (4.4%) |
-100% | 1 (4.4%) |
-unknown | 18 (78.3%) |